21.4 USD
-0.39 (-1.79%)
We assign a fundamental rating of 3 out of 10 to SRPT. SRPT was compared to 525 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- SRPT had negative earnings in the past year.
- SRPT had a negative operating cash flow in the past year.
- SRPT had negative earnings in 4 of the past 5 years.
- SRPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of -7.77%, SRPT belongs to the best of the industry, outperforming 85.33% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -20.57%, SRPT belongs to the top of the industry, outperforming 83.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SRPT has a Gross Margin of 76.25%. This is amongst the best in the industry. SRPT outperforms 84.19% of its industry peers.
- SRPT's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
- SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SRPT has been increased compared to 1 year ago.
- Compared to 5 years ago, SRPT has more shares outstanding
- Compared to 1 year ago, SRPT has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.00, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
- SRPT has a Altman-Z score (0.00) which is in line with its industry peers.
- A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
- SRPT has a Debt to Equity ratio of 0.78. This is in the lower half of the industry: SRPT underperforms 72.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC7.54%
2.3 Liquidity
- A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
- SRPT has a Current ratio of 2.95. This is in the lower half of the industry: SRPT underperforms 64.76% of its industry peers.
- SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
- SRPT has a Quick ratio of 1.79. This is in the lower half of the industry: SRPT underperforms 76.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
- SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
- The Revenue has grown by 47.15% in the past year. This is a very strong growth!
- The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
- SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.98% yearly.
- SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.08% yearly.
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.98%
Revenue Next Year13.57%
Revenue Next 2Y-8.88%
Revenue Next 3Y-7.36%
Revenue Next 5Y-5.08%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
- A Price/Forward Earnings ratio of 9.11 indicates a reasonable valuation of SRPT.
- SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 98.67% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.32. SRPT is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.11 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as SRPT's earnings are expected to decrease with -6.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
5. Dividend
5.1 Amount
- No dividends for SRPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
Can you provide the valuation status for SAREPTA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
What is the profitability of SRPT stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
How financially healthy is SAREPTA THERAPEUTICS INC?
The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 3 / 10.